197819782009
Lv7
5010 积分
2022-09-07 加入
-
The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China: Erratum
16天前
已关闭
-
Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target
1个月前
已完结
-
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
1年前
已完结
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
1年前
已完结
-
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
1年前
已完结
-
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
1年前
已完结
-
The future of liquid biopsy
1年前
已完结
-
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
2年前
已完结
-
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios
2年前
已完结
-
Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs
2年前
已完结